Comparative drug info labeling helps doctors

Share this article:

Stanford University researchers say that drug labeling would be much more informative for doctors and patients if it had to include comparative effectiveness information.

Writing in the New England Journal of Medicine's online edition, researchers led by Stanford Prevention Research Center's associate professor of medicine, Randall Stafford, said that without comparative effectiveness information, drug labels “may create confusion as manufacturers strive to insulate their products from price competition through differentiation that is unrelated to health outcomes. If the FDA label were required to indicate what is and is not known about a product's superiority to other treatments, then clinicians, patients and payers would be less willing to pay more for a treatment without proof that it improved health outcomes.”

The researchers said many new drugs are approved on the basis of demonstrated superiority to placebo, creating a climate that favors development of “me-too” drugs.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"